Elanco Animal Health Incorporated (NYSE:ELAN) Shares Acquired by Skylands Capital LLC

Skylands Capital LLC increased its position in Elanco Animal Health Incorporated (NYSE:ELAN) by 36.2% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 504,500 shares of the company’s stock after buying an additional 134,150 shares during the quarter. Skylands Capital LLC owned about 0.10% of Elanco Animal Health worth $6,109,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently modified their holdings of ELAN. AM Squared Ltd acquired a new stake in shares of Elanco Animal Health during the third quarter worth $34,000. Wilmington Savings Fund Society FSB acquired a new stake in shares of Elanco Animal Health during the third quarter worth $35,000. Farther Finance Advisors LLC raised its position in shares of Elanco Animal Health by 158.7% during the third quarter. Farther Finance Advisors LLC now owns 3,332 shares of the company’s stock worth $49,000 after purchasing an additional 2,044 shares during the period. Venturi Wealth Management LLC raised its position in shares of Elanco Animal Health by 89.9% during the third quarter. Venturi Wealth Management LLC now owns 3,382 shares of the company’s stock worth $50,000 after purchasing an additional 1,601 shares during the period. Finally, Blue Trust Inc. raised its position in shares of Elanco Animal Health by 2,129.2% during the third quarter. Blue Trust Inc. now owns 3,968 shares of the company’s stock worth $57,000 after purchasing an additional 3,790 shares during the period. 97.48% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on the company. Stifel Nicolaus dropped their price target on Elanco Animal Health from $18.00 to $16.00 and set a “buy” rating on the stock in a research report on Friday. Morgan Stanley dropped their price target on Elanco Animal Health from $15.00 to $14.00 and set an “equal weight” rating on the stock in a research report on Wednesday, January 29th. Barclays upped their price target on Elanco Animal Health from $19.00 to $20.00 and gave the company an “overweight” rating in a research report on Friday, November 8th. Leerink Partnrs raised Elanco Animal Health to a “hold” rating in a research report on Monday, December 2nd. Finally, UBS Group assumed coverage on Elanco Animal Health in a research report on Monday, December 9th. They set a “buy” rating and a $18.00 price target on the stock. One analyst has rated the stock with a sell rating, four have assigned a hold rating and three have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $16.00.

Elanco Animal Health Stock Performance

Shares of ELAN stock opened at $11.02 on Monday. The firm has a market cap of $5.45 billion, a P/E ratio of 27.54, a PEG ratio of 2.50 and a beta of 1.42. The stock’s 50-day moving average is $11.80 and its two-hundred day moving average is $13.10. Elanco Animal Health Incorporated has a fifty-two week low of $10.77 and a fifty-two week high of $18.80. The company has a debt-to-equity ratio of 0.66, a current ratio of 2.55 and a quick ratio of 1.31.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.